Introduction. Multiple myeloma (MM) represents a population with an increased risk of
developing infection up to 10-fold if compared with controls. Moreover, patients treated with …

Background. Infections represent a major cause of toxicity in newly diagnosed multiple
myeloma (NDMM) patients, and their incidence is higher during the first 4 months of therapy …

Background: Lenalidomide is an immune modulator, approved for use since 2005 for the
treatment of multiple myeloma (MM) patients. Its use is associated with an increased risk of …

The immunomodulatory drug lenalidomide is highly effective against newly diagnosed and
relapsed/refractory multiple myeloma (MM), but serious and even fatal infections have been …

Aim. To study infectious complications and factors attributable to them as reported in multiple
myeloma (MM) patients in the framework of state-of-the-art anticancer therapy. Materials & …

Lenalidomide-based regimens are effective treatment options for patients with
relapsed/refractory multiple myeloma (RRMM). However, they are associated with an …

In a retrospective study that assessed the incidence, type and major factors affecting
infections in 127 patients with multiple myeloma (MM) receiving lenalidomide-based …

Abstract Abstract 2876 Poster Board II-852 Multiple myeloma (MM) patients (pts) are
immunosuppressed given the underlying disease, previous treatments and …

Infections are an important cause of morbidity and mortality in newly diagnosed multiple
myeloma (NDMM), but the real-world risk using modern induction regimens such as …

Background Patients with multiple myeloma (MM) remain at an increased risk of infection
due to the disease process, as well as the ensuing treatments. Methods We performed a …